CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
TAK-788 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03928327
NCT03928327Phase 1Completed
CompareCT.gov

A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction With Itraconazole and Rifampin in Healthy Adult Subjects

Millennium Pharmaceuticals, Inc.·interventional·Posted Apr 26, 2019·Updated Aug 21, 2020

In Brief

A Phase 1 clinical trial evaluating TAK-788, Itraconazole, and 1 other intervention for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 26, 2019
Enrollment StartMay 2, 2019
Primary CompletionAug 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.2 years ago

Interventions

TAK-788drug

TAK-788 Capsules

Itraconazoledrug

Itraconazole Oral solution

Rifampindrug

Rifampin Capsules